Overview

Gender

male

Dr. Sinil Kim is the Chief Medical Officer and VP of Oncology at Mirna Therapeutics, Inc.

Dr. Kim received his B.S. in Chemistry and M.D. from the University of Washington, completed his Hematology/Oncology post-doctoral fellowship at University of California San Diego and served as an Associate Professor.

He co-founded DepoTech Corp to work on DepoCyt, DepoDur and Exparel, and subsequently moved to Bristol-Myers Squibb to join the Erbitux BLA filing team.

Most recently, Dr. Kim served as the Global Clinical Leader for Inlyta and Torisel at Pfizer, Inc.